echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Jiangsu Institute of Traditional Chinese Medicine obtained the implied license of Bakuchichi total glucoside capsules for clinical trials

    Jiangsu Institute of Traditional Chinese Medicine obtained the implied license of Bakuchichi total glucoside capsules for clinical trials

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
    2 of traditional Chinese medicine
    .
    According to the data from Minet.
    com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
    .

     
     
     Source: CDE official website
     
    Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
    It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
    ), which has the effect of warming kidney and helping yang.
    Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
    .
     
    According to the data of Minet.
    com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
    Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
    .
     
    Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
    Source: MED2.
    0 China Drug Evaluation Database
     
      According to data from Minet.
    com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
    in China will exceed 30 billion yuan .
     
      In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
    .
     
      2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
      Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
      Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
    .
      Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
    2 of traditional Chinese medicine
    .
    According to the data from Minet.
    com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
    .

     
     
     Source: CDE official website
     
      Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
    It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
    ), which has the effect of warming kidney and helping yang.
    Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
    .
     
      According to the data of Minet.
    com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
    Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
    .
     
      Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
      Source: MED2.
    0 China Drug Evaluation Database
     
      According to data from Minet.
    com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
    in China will exceed 30 billion yuan .
     
      In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
    .
     
      2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
      Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
      Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
    .
      Recently, the CDE official website shows that the Jiangsu Provincial Institute of Traditional Chinese Medicine has obtained the implied license for clinical trials for the total psoralen capsules declared as a new drug of category 1.
    2 of traditional Chinese medicine
    .
    According to the data from Minet.
    com, since 2020, 8 new types of musculoskeletal system TCM Class 1 drugs have been submitted for marketing/clinical applications, 2 of which have been approved for marketing, and the remaining 6 have been approved for clinical use
    .

     
     
     
     Source: CDE official website
     
     
      Psoralea total glycosides capsule is a new orthopaedic traditional Chinese medicine.
    It is mainly composed of Psoralea total glycosides extract (including psoralen, isopsoralea, etc.
    ), which has the effect of warming kidney and helping yang.
    Primary osteoporosis caused by deficiency, symptoms such as cold pain in the waist and knees
    .
     
      According to the data of Minet.
    com, since 2020, two new types of musculoskeletal system Chinese medicine category 1 drugs have been submitted for marketing in China, and both have been approved for production.
    Tablets) and Yili Pharmaceutical’s Huzhen Qingfeng Capsules; 6 category 1 new drugs have submitted clinical applications, all of which have been approved for clinical use
    .
     
      Class 1 new drugs of traditional Chinese medicine for the musculoskeletal system declared for marketing/clinical in 2020
     
      Source: MED2.
    0 China Drug Evaluation Database
     
      According to data from Minet.
    com, in 2020, the sales volume of Chinese patent medicines for the musculoskeletal system in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and physical pharmacies
    in China will exceed 30 billion yuan .
    Hospital Hospital Hospital Pharmacy Pharmacy Pharmacy
     
      In the Chinese patent medicine terminal of physical pharmacies in Chinese cities, it is expected that in 2021, the sales volume of five categories of drugs will exceed 10 billion yuan, and the musculoskeletal system Chinese patent medicine is one of them
    .
    medicines medicines medicines
     
      2021E Top 5 products of Chinese patent medicines for musculoskeletal system in Chinese urban physical pharmacies
      Source: Minet.
    com China's urban physical pharmacy terminal competition pattern
     
      Judging from the ranking of Chinese patent medicine products in the musculoskeletal system, the total market share of TOP5 products exceeds 30%, of which Shujin Jianyao Pills topped the list with sales of over 1 billion yuan
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.